Welcome to our dedicated page for Oramed Pharmaceuticals news (Ticker: ORMP), a resource for investors and traders seeking the latest updates and insights on Oramed Pharmaceuticals stock.
Oramed Pharmaceuticals Inc. develops oral drug delivery technology for drugs commonly delivered by injection. Its Protein Oral Delivery, or POD, platform is designed to protect therapeutic proteins in the gastrointestinal tract and improve absorption, with company updates centered on oral insulin development and related clinical-stage programs.
Oramed news also covers its expanded strategic investment activity, including positions and agreements involving Scilex and Alpha Tau Medical, as well as financial results, cash returns, dividend actions, shareholder rights matters, and other capital-structure developments. Recurring announcements connect the company’s pharmaceutical platform with its investment portfolio, governance actions, and operating expenses.
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) announced that CEO Nadav Kidron will present a company overview at the H.C. Wainwright 22nd Annual Global Investment Conference, scheduled for September 14-16, 2020. Kidron's presentation will take place on September 15 at 1:30 PM Eastern. Oramed specializes in oral drug delivery solutions, aiming to transform diabetes treatment with its lead candidate, ORMD-0801, the first oral insulin capsule. The company has completed multiple Phase II clinical trials and is also developing an oral GLP-1 analog capsule, ORMD-0901.
Oramed Pharmaceuticals announced positive feedback from the FDA during its End of Phase 2 meeting regarding its oral insulin, ORMD-0801. The FDA's feedback paves the way for Oramed to initiate two concurrent Phase 3 clinical trials after protocol review. Successful trials could lead to a Biologics License Application (BLA), which would grant 12 years of marketing exclusivity for ORMD-0801. The company aims to address unmet needs in diabetes treatment with this innovative oral insulin product.
Oramed Pharmaceuticals announced positive preliminary results from a pilot study on its oral insulin candidate, ORMD-0801, aimed at treating type 2 diabetes patients with non-alcoholic steatohepatitis (NASH). The study showed that ORMD-0801 was safe and well tolerated, with a mean reduction of 6.9% in liver fat content after 12 weeks. Additionally, significant decreases in gamma-glutamyltransferase and fasting insulin levels were observed. These findings were presented at the 80th American Diabetes Association Scientific Sessions, signaling potential for further research and clinical trials.